Clinical Trial

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally advanced/metastatic triple-negative breast cancer(TNBC)
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-07-30
Trial Details
NCT Number NCT06419621
Lead Sponsor Biotheus Inc.
Conditions Triple Negative Breast Cancer(TNBC)
Enrollment 392 participants
Start Date 2024-06-11
Primary Completion 2027-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-29